Mehta N - Search Results

1

Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.

Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Salama JK, et al. Among authors: mehta n. Cancer. 2012 Jun 1;118(11):2962-70. doi: 10.1002/cncr.26611. Epub 2011 Oct 21. Cancer. 2012. PMID: 22020702 Free article. Clinical Trial.

2

Does the number of lymph nodes examined in patients with lymph node-negative breast carcinoma have prognostic significance?

Salama JK, Heimann R, Lin F, Mehta N, Chmura SJ, Singh R, Kao J. Salama JK, et al. Among authors: mehta n. Cancer. 2005 Feb 15;103(4):664-71. doi: 10.1002/cncr.20830. Cancer. 2005. PMID: 15641038 Free article.

3

An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease.

Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, Haraf DJ, Hellman S, Weichselbaum RR. Salama JK, et al. Among authors: mehta n. Clin Cancer Res. 2008 Aug 15;14(16):5255-9. doi: 10.1158/1078-0432.CCR-08-0358. Clin Cancer Res. 2008. PMID: 18698045 Clinical Trial.

4

Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.

Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR. Mehta N, et al. Int J Oncol. 2004 Dec;25(6):1677-83. Int J Oncol. 2004. PMID: 15547705 Clinical Trial.

5

Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies.

Salama JK, Mundt AJ, Roeske J, Mehta N. Salama JK, et al. Among authors: mehta n. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1170-6. doi: 10.1016/j.ijrobp.2006.02.041. Epub 2006 May 26. Int J Radiat Oncol Biol Phys. 2006. PMID: 16730136

6

Intensity-modulated radiation therapy in gynecologic malignancies.

Salama JK, Roeske JC, Mehta N, Mundt AJ. Salama JK, et al. Among authors: mehta n. Curr Treat Options Oncol. 2004 Apr;5(2):97-108. doi: 10.1007/s11864-004-0042-2. Curr Treat Options Oncol. 2004. PMID: 14990204 Review.

7

Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity.

Lopez CA, Kimchi ET, Mauceri HJ, Park JO, Mehta N, Murphy KT, Beckett MA, Hellman S, Posner MC, Kufe DW, Weichselbaum RR. Lopez CA, et al. Among authors: mehta n. Mol Cancer Ther. 2004 Sep;3(9):1167-75. Mol Cancer Ther. 2004. PMID: 15367711

8

Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma.

Murphy KT, Wardak A, Beckett MA, Lopez CA, Mehta N, Kimchi E, Salloum RM, Jaskowiak NT, Posner MC, Ohno T, Kufe DW, Weichselbaum RR, Mauceri HJ. Murphy KT, et al. Among authors: mehta n. Cancer Chemother Pharmacol. 2005 Sep;56(3):317-21. doi: 10.1007/s00280-004-0986-8. Epub 2005 May 11. Cancer Chemother Pharmacol. 2005. PMID: 15887016

9

Predictors of tumor control in patients treated with linac-based stereotactic radiosurgery for metastatic disease to the brain.

Schomas DA, Roeske JC, MacDonald RL, Sweeney PJ, Mehta N, Mundt AJ. Schomas DA, et al. Among authors: mehta n. Am J Clin Oncol. 2005 Apr;28(2):180-7. doi: 10.1097/01.coc.0000143017.69880.04. Am J Clin Oncol. 2005. PMID: 15803014

10

Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy.

Mehta N, Yamada SD, Rotmensch J, Mundt AJ. Mehta N, et al. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1004-9. doi: 10.1016/s0360-3016(03)00753-3. Int J Radiat Oncol Biol Phys. 2003. PMID: 14575831

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,637 results

Search Page